Sangamo Therapeutics
(SGMO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2009 | 12-2008 | 12-2007 | 12-2006 | 12-2005 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -18,587 | -24,302 | -21,480 | -17,864 | -13,293 |
| Depreciation Amortization | 860 | -536 | -1,871 | -686 | 488 |
| Accounts receivable | 284 | -161 | 9 | 647 | -360 |
| Other Working Capital | 3,391 | 685 | 4,846 | -3,724 | 8,414 |
| Other Operating Activity | 7,915 | 6,969 | 2,428 | 7,149 | 682 |
| Operating Cash Flow | $-6,137 | $-17,345 | $-16,068 | $-14,478 | $-4,069 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -18,906 | 24,529 | -25,269 | -11,858 | -4,001 |
| PPE Investments | -272 | -739 | -1,369 | -374 | -428 |
| Investing Cash Flow | $-19,178 | $23,790 | $-26,638 | $-12,232 | $-4,429 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 26,763 | 1,847 | 42,279 | 20,905 | 18,379 |
| Financing Cash Flow | $26,763 | $1,847 | $42,279 | $20,905 | $18,379 |
| Exchange Rate Effect | 302 | -1,158 | N/A | N/A | N/A |
| Beginning Cash Position | 19,409 | 12,275 | 12,702 | 18,507 | 8,626 |
| End Cash Position | 21,159 | 19,409 | 12,275 | 12,702 | 18,507 |
| Net Cash Flow | $1,750 | $7,134 | $-427 | $-5,805 | $9,881 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,137 | -17,345 | -16,068 | -14,478 | -4,069 |
| Capital Expenditure | -272 | -739 | -1,369 | -374 | -428 |
| Free Cash Flow | -6,409 | -18,084 | -17,437 | -14,852 | -4,497 |